{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-004800","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.793624+00:00","generated_at":"2026-05-16T01:28:17.792201+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moleculin Biotech raises ~$8.3M via warrant exercise inducement; issues new Series H warrants for 6.4M shares","bullets":["Holders exercise 2,122,652 existing warrants at $3.90 per share; gross proceeds ~$8.3M.","Company issues new Series H warrants for up to 6,367,956 shares (300% of exercised) with 5-year term.","New warrant exercise price = lesser of $3.90 or lowest VWAP in 5 trading days post-announcement; floor $0.962.","Shareholder approval required for issuance of new warrant shares; resale registration to be filed by March 31, 2026.","Roth Capital served as financial advisor, receiving 7% of gross proceeds from the warrant exercise."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-004800","json":"https://secwatch.observer/filing/0001437749-26-004800.json","markdown":"https://secwatch.observer/filing/0001437749-26-004800.md","text":"https://secwatch.observer/filing/0001437749-26-004800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/0001437749-26-004800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/mbrx20260219_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:28:17.792201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbb9bb16a07e3ceb3865028ae809b07514ac9efc","claim":"Moleculin Biotech, Inc. entered into Inducement Letter with holders of certain existing warrants valued at approximately $8.3 million (effective 2026-02-19).","evidence_excerpt":"On February 19, 2026, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (each, an “Inducement Letter”) with holders of certain existing warrants (the “Holders”) to purchase up to 2,122,652 shares of Company common stock with an exercise price of $3.90 per share (the “Existing Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/0001437749-26-004800-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"holders of certain existing warrants"},{"label":"Value","value":"approximately $8.3 million"},{"label":"Effective","value":"2026-02-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}